Emergent BioSolutions Unveils Expanded Maryland Facility

On May 10, 2017, Emergent BioSolutions held a ribbon cutting ceremony with Rick Bright, PhD, director of the Biomedical Advanced Research and Development Authority (BARDA) and Daniel J. Abdun-Nabi, president and CEO of Emergent, to mark the formal opening of the company’s newly expanded Center for Innovation in Advanced Development and Manufacturing at its Bayview Campus in Baltimore.

The facility is one of three centers designated by the US Department of Health and Human Services to provide advanced development and manufacturing of medical countermeasures to support the US government’s national security and public health emergency needs. Emergent has doubled the Bayview facility’s footprint to 112,000 square feet with investments to the original 56,000-square-foot facility purchased by the company in 2009. The facility, comprised of laboratory, manufacturing, and office space, offers flexible manufacturing of drug substance from microbial, cell culture, or viral production platforms and is equipped with disposable manufacturing technology.

The new suite within the expanded facility is expected to come online with cGMP production capabilities in late 2018. Since its inception, the Emergent Center for Innovation in Advanced Development and Manufacturing has been awarded four task orders by BARDA to develop Ebola and Marburg therapeutics and a Zika vaccine.